Report cover image

Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Jan 04, 2023
Length 97 Pages
SKU # GBDT17666593

Description

Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in bladder cancer therapeutics.

Synopsis
  • In 2022, there will be more than 460,000 diagnosed incident cases of bladder cancer across 16 pharmaceutical markets.
  • There are a good number of marketed innovator drugs for the treatment of bladder cancer, mostly checkpoint inhibitors.
  • The bladder cancer pipeline consists of three products in pre-registration and 30 products in Phase III development.
  • Commercial sponsors dominate clinical trial development in bladder cancer, with the US emerging as the key country for conducting Phase III trials.
  • During the past 12 months, six strategic alliances and two merger and acquisition transactions involving bladder cancer assets were successfully completed.
  • Regulatory decisions are expected soon for key innovator molecules from ImmunityBio and Ferring Pharmaceuticals.
Scope

GlobalData’s bladder cancer: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the bladder cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

97 Pages
  • Report Scope
  • Abbreviations
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Diagnosed Incident Cases of Bladder Cancer in 2022 and 2027
  • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in Bladder Cancer
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile: Roche's Tecentriq
    • Marketed Drug Profile: Merck KGaA/EMD Serono's Bavencio
    • Marketed Drug Profile: Merck's Oncotice
    • Marketed Drug Profile: AstraZeneca's Imfinzi
    • Marketed Drug Profile: Astellas's Padcev
    • Marketed Drug Profile: Janssen's Balversa
    • Marketed Drug Profile: Bristol Myers Squibb/Ono Pharma's Opdivo/Opdyta
    • Marketed Drug Profile: Merck's Keytruda
    • Marketed Drugs - Manufacturer Price (in $/mg) for Intravenous and Oral Formulations in Bladder Cancer
    • Marketed Drugs - Manufacturer Price ($/mg)
    • Marketed Drugs - Time to Pricing and Reimbursement for Atezolizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Avelumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Durvalumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Enfortumab Vedotin
    • Marketed Drugs - Time to Pricing and Reimbursement for Erdafitinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Nivolumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Pembrolizumab
    • Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in Bladder Cancer
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in Bladder Cancer
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Oncology and in Bladder Cancer
    • Clinical Trials in Bladder Cancer - Historical Overview
    • Clinical Trials in Bladder Cancer - Overview by Phase
    • Clinical Trials in Bladder Cancer - Overview by Status
    • Clinical Trials in Bladder Cancer - Overview by Phase for Ongoing and Planned Trial
    • Clinical Trials in Bladder Cancer - Trials with a Virtual Component
    • Clinical Trials in Bladder Cancer - Geographic Overview
    • Clinical Trials in Bladder Cancer - Single-Country and Multinational Trials by Region
    • Clinical Trials in Bladder Cancer - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in Bladder Cancer - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in Bladder Cancer - Overview by Endpoint Status
    • Clinical Trials in Bladder Cancer - Overview by Race and Ethnicity
    • Clinical Trials in Bladder Cancer - Enrollment Data
    • Clinical Trials in Bladder Cancer - Overview of Sites by Geography
    • Clinical Trials in Bladder Cancer - Top 20 Countries for Trial Sites
    • Clinical Trials in Bladder Cancer - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for Bladder Cancer
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Bladder Cancer by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in Bladder Cancer
    • Commercial Assessment - Key Market Players in Bladder Cancer
    • Future Market Catalysts - Upcoming Market Catalysts in Bladder Cancer
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • Contact Us - A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us